Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal protein vaccine (Sanofi)
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is an investigational trivalent pneumococcal protein recombinant vaccine (PPrV) developed by Sanofi for the prevention of infections caused by *Streptococcus pneumoniae*. Unlike traditional polysaccharide-based vaccines that target specific serotypes, this vaccine utilizes three highly conserved recombinant protein antigens: pneumococcal choline-binding protein A (PcpA), pneumococcal histidine triad protein D (PhtD), and a genetically detoxified pneumolysin mutant (PlyD1). By targeting these conserved surface proteins, the vaccine aims to provide broad, serotype-independent protection against pneumococcal disease. It is formulated with an aluminum adjuvant to enhance immunogenicity and has been evaluated in Phase 1 clinical trials for safety and tolerability in adults, toddlers, and infants.
- Other names
- Trivalent pneumococcal protein recombinant vaccinePPrV-SanofiInvestigational trivalent pneumococcal protein recombinant vaccine
02
Targets
Ply (Pneumolysin)PhtD (Pneumococcal histidine triad protein D)PcpA (Pneumococcal choline-binding protein A)
Beyond the preview
Go deeper on pneumococcal protein vaccine (Sanofi).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal protein vaccine (Sanofi).